Phase II cancer clinical trials with heterogeneous patient populations

Journal of Biopharmaceutical Statistics

Volumn 22, Issue 2, 2012, Pages 312-328

  Jung, Sin Ho ^a   Chang, Myron N ^b   Kang, Sun J ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Downstate Health Sciences University   (United States)

Author keywords

Conditional power; Conditional type I error; Minimax design; Optimal design; Prevalence

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER RESEARCH; HIGH RISK PATIENT; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL;

ALGORITHMS; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, STATISTICAL; NEOPLASMS; RESEARCH DESIGN; SAMPLE SIZE; THERAPIES, INVESTIGATIONAL;

EID: 84856946741     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2010.536873     Document Type: Article

References (12)

1. Jung, S. H. (2008). Randomized Phase II trials with a prospective control. Statistics in Medicine 27:568-583.
2. Jung, S. H., Carey, M., Kim, K. M. (2001). Graphical search for two-stage Phase II clinical trials. Controlled Clinical Trials 22:367-372. (Pubitemid 32763103)
3. Jung, S. H., Lee, T. Y., Kim, K. M., George, S. (2004). Admissible two-stage designs for Phase II cancer clinical trials. Statistics in Medicine 23:561-569. (Pubitemid 38208184)
4. Jung, S. H., Owzar, K., George, S. L., Lee, T. Y. (2006). p-Value calculation for multistage Phase II cancer clinical trials (with discussion). Journal of Biopharmaceutical Statistics 16:765-783.
5. London, W. B., Chang, M. N. (2005). One- and two-stage designs for stratified Phase II clinical trials. Statistics in Medicine 24:2597-2611. (Pubitemid 41300797)
6. Makuch, R. W., Simon, R. M. (1980). Sample size considerations for non-randomized comparative studies. Journal of Chronic Disease 33:175-181. (Pubitemid 10162548)
7. Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., Smith, M. A. (2005). Design issues of randomized Phase II trials and a proposal for Phase II screening trials. Journal of Clinical Oncology 23(28):7199-7206.
8. Simon, R. (1989). Optimal two-stage designs for Phase II clinical trials. Controlled Clinical Trials 10:1-10. (Pubitemid 19099520)
9. Sposto, R., Gaynon, P. S. (2009). An adjustment for patient heterogeneity in the design of two-stage Phase II trials. Statistics in Medicine 28:2566-2579.
10. Thall, P. F., Simon, R. (1990). Incorporating historical control data in planning Phase II clinical trials. Statistics in Medicine 9:215-228. (Pubitemid 20252730)
11. Thall, P. F., Simon, R., Ellenberg, S. S. (1989). A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45:537-547. (Pubitemid 19165264)
12. Wathen, J. K., Thall, P. F., Cook, J. D., Estey, E. H. (2008). Accounting for patient heterogeneity in Phase II clinical trials. Statistics in Medicine 27:2802-2815. (Pubitemid 351982677)